Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -1.59
- Piotroski Score 1.00
- Grade Buy
- Symbol (TSVT)
- Company 2seventy bio, Inc.
- Price $3.62
- Changes Percentage (14.51%)
- Change $0.46
- Day Low $3.16
- Day High $3.73
- Year High $6.40
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/04/2025
- Fiscal Year End N/A
- Average Stock Price Target $2.00
- High Stock Price Target $2.00
- Low Stock Price Target $2.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$4.35
- Trailing P/E Ratio -0.9
- Forward P/E Ratio -0.9
- P/E Growth -0.9
- Net Income $-217,570,000
Income Statement
Quarterly
Annual
Latest News of TSVT
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
2seventy bio Inc (TSVT) Q3 2024 Earnings Call Highlights: Strong Abecma Growth and Strategic ...
CEO Chip Baird discussed the steady growth in demand for Abecma in the market, driven by increased manufacturing capacity and awareness of its benefits. CFO Vicki Eatwell highlighted improved margins ...
By Yahoo! Finance | 1 week ago -
Broker Revenue Forecasts For 2seventy bio, Inc. (NASDAQ:TSVT) Are Surging Higher
Analysts have upgraded revenue forecasts for 2seventy bio, Inc., leading to a 11% share price increase. Despite a projected revenue decline, reduced losses indicate progress towards profitability. How...
By Yahoo! Finance | 4 months ago
